$670 Million is the total value of SECTORAL ASSET MANAGEMENT INC's 65 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 106.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APRE | New | APREA THERAPEUTICS | $67,474,000 | – | 1,470,339 | +100.0% | 10.07% | – |
| BSX | Buy | BOSTON SCIENTIFIC | $23,441,000 | +159.3% | 518,376 | +133.3% | 3.50% | +124.2% |
| BMRN | Buy | BIOMARIN PHARMAC INC | $18,931,000 | +98.1% | 223,901 | +57.9% | 2.82% | +71.3% |
| EVH | Buy | EVOLENT HEALTH INC | $18,093,000 | +58.7% | 1,999,172 | +26.1% | 2.70% | +37.3% |
| ATRC | Buy | ATRICURE INC | $17,352,000 | +55.5% | 533,756 | +19.3% | 2.59% | +34.5% |
| RETA | New | REATA PHARMACEUTIC | $16,487,000 | – | 80,650 | +100.0% | 2.46% | – |
| FGEN | Buy | FIBROGEN INC | $15,732,000 | +27.6% | 366,806 | +10.0% | 2.35% | +10.3% |
| RCM | Buy | R1 RCM INC | $15,045,000 | +70.3% | 1,159,073 | +17.1% | 2.24% | +47.2% |
| PTLA | Buy | PORTOLA PHARMACEUTIC | $14,476,000 | -1.2% | 606,189 | +10.9% | 2.16% | -14.6% |
| HRC | Buy | HILL-ROM HLDS INC | $13,919,000 | +50.1% | 122,599 | +39.2% | 2.08% | +29.9% |
| VCRA | Buy | VOCERA COMMUNICATI | $12,156,000 | +3.0% | 585,528 | +22.3% | 1.81% | -10.9% |
| TFX | New | TELEFLEX INC | $10,938,000 | – | 29,057 | +100.0% | 1.63% | – |
| STML | Buy | STEMLINE THERAPEUT | $10,876,000 | +54.2% | 1,023,159 | +51.0% | 1.62% | +33.4% |
| TRHC | Buy | TABULA RASA HEALTH | $10,086,000 | +52.2% | 207,182 | +71.8% | 1.50% | +31.7% |
| CSII | New | CARDIOVASCULAR SYS | $9,999,000 | – | 205,782 | +100.0% | 1.49% | – |
| BIIB | New | BIOGEN INC | $9,656,000 | – | 32,542 | +100.0% | 1.44% | – |
| HMSY | Buy | HMS HOLDINGS CORP | $8,888,000 | +231.8% | 300,275 | +286.3% | 1.33% | +187.0% |
| LLY | Buy | LILLY ELI & CO | $8,643,000 | +38.6% | 65,765 | +17.9% | 1.29% | +19.9% |
| AZN | New | ASTRAZENECAsponsored adr | $7,868,000 | – | 157,800 | +100.0% | 1.17% | – |
| PRAH | New | PRA HEALTH SCIENCE | $7,771,000 | – | 69,915 | +100.0% | 1.16% | – |
| NXTC | New | NEXTCURE INC | $7,041,000 | – | 125,000 | +100.0% | 1.05% | – |
| SILK | New | SILK ROAD MEDICAL | $6,873,000 | – | 170,200 | +100.0% | 1.03% | – |
| QURE | Buy | UNIQURE N.V. | $6,270,000 | +440.1% | 87,500 | +196.6% | 0.94% | +368.0% |
| ACAD | New | ACADIA PHARMACEUTCLS | $6,180,000 | – | 144,450 | +100.0% | 0.92% | – |
| UNH | New | UNITEDHEALTH GRP INC | $6,092,000 | – | 20,721 | +100.0% | 0.91% | – |
| MTEM | Buy | MOLECULAR TEMPLATES | $6,050,000 | +211.5% | 432,585 | +46.8% | 0.90% | +169.6% |
| AMGN | New | AMGEN INC | $3,954,000 | – | 16,403 | +100.0% | 0.59% | – |
| BPMC | New | BLUEPRINT MEDICINES | $3,605,000 | – | 45,000 | +100.0% | 0.54% | – |
| VRTX | Buy | VERTEX PHARMACEUTICL | $3,519,000 | +46.6% | 16,071 | +13.4% | 0.52% | +26.8% |
| ILMN | New | ILLUMINA INC | $3,234,000 | – | 9,750 | +100.0% | 0.48% | – |
| VCEL | New | VERICEL CORP | $2,401,000 | – | 138,000 | +100.0% | 0.36% | – |
| SGEN | New | SEATTLE GENETICS INC | $1,714,000 | – | 15,000 | +100.0% | 0.26% | – |
| INCY | New | INCYTE CORPORATION | $1,310,000 | – | 15,000 | +100.0% | 0.20% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOMARIN PHARMAC INC | 42 | Q3 2023 | 6.7% |
| PTC THERAPEUTICS INC | 42 | Q3 2023 | 2.7% |
| DR REDDYS LABS LTD | 42 | Q3 2023 | 2.0% |
| GILEAD SCIENCES INC | 38 | Q3 2023 | 8.4% |
| INCYTE CORPORATION | 38 | Q3 2023 | 5.2% |
| VERTEX PHARMACEUTICL | 38 | Q3 2023 | 6.0% |
| AMICUS THERAPEUTICS INC | 37 | Q3 2023 | 6.6% |
| PFIZER INC | 35 | Q3 2023 | 6.3% |
| MERCK & CO. INC | 34 | Q3 2023 | 6.4% |
| MEDTRONIC PLC | 33 | Q3 2023 | 4.4% |
View SECTORAL ASSET MANAGEMENT INC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aprea Therapeutics, Inc. | February 12, 2021 | 163,681 | 0.8% |
| LA JOLLA PHARMACEUTICAL CO | February 13, 2020 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 13, 2018 | 1,426,862 | 4.4% |
| Advaxis, Inc. | February 10, 2017 | 690,074 | 1.7% |
| AMICUS THERAPEUTICS INC | February 10, 2017 | 5,100,198 | 3.6% |
| OncoMed Pharmaceuticals Inc | February 12, 2016 | ? | ? |
| IRONWOOD PHARMACEUTICALS INC | February 13, 2015 | ? | ? |
| SEQUENOM INC | February 12, 2014 | ? | ? |
| INCYTE CORP | February 11, 2014 | 1,185,260 | 0.7% |
| INTERMUNE INC | February 11, 2014 | ? | ? |
View SECTORAL ASSET MANAGEMENT INC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-13 |
| SC 13G | 2023-02-13 |
| 13F-HR | 2023-02-10 |
View SECTORAL ASSET MANAGEMENT INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.